Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: The AORTA study

Vascular Health and Risk Management

Volumn 7, Issue 1, 2011, Pages 383-390

  Takami, Takeshi ^a   Saito, Yoshihiko ^b  

^a Clinic Jingumae   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Augmentation index; Brachial ankle pulse wave velocity; Central blood pressure; Left ventricular mass index; Olmesartan azelnidipine

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZELNIDIPINE; AZETIDINE 2 CARBOXYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE; OLMESARTAN; TETRAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; ECHOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CHI-SQUARE DISTRIBUTION; DIHYDROPYRIDINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMIDAZOLES; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856374641     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S21991     Document Type: Article

References (40)

1. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3-107. [Erratum: Hypertens Res. 2009;32:318].
2. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduct Artery Function Evaluation (CAFÉ) study. Circulation. 2006;113:1213-1225.
3. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50:197-203.
4. Miyashita H, Aizawa A, Hashimoto J, et al. Cross-sectional characterization of all classes of antihypertensives in terms of central blood pressure in Japanese hypertensive patients. Am J Hypertens. 2010; 23:260-268.
5. Matsui Y, Eguchi K, O'Rourke MF, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension. 2009;54:716-723.
6. Kondo T, Goto R, Sonoda K, et al. Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients. Intern Med. 2010;49:637-643.
7. Eguchi K, Tomizawa H, Ishikawa J, et al. Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure. J Cardiovasc Pharmacol. 2007;49: 394-400.
8. Nakamura T, Sugaya T, Kawagoe Y, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007; 333:321-326.
9. Melenovsky V, Borlaug BA, Fetics B, Kessler K, Shively L, Kass DA. Estimation of central pressure augmentation using automated radial artery tonometry. J Hypertens. 2007;25:1403-1409.
10. Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashina A. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. Hypertens Res. 2007;30:219-228.
11. Richardson CJ, Maki-Petaja KM, McDonnell BJ, Hickson SS, Wilkinson IB, McEniery CM. Comparison of estimates of central systolic blood pressure and peripheral augmentation index obtained from the Omron HEM-9000 AI and SphygmoCor systems. Artery Res. 2009;3:24-31.
12. Hickson SS, Butlin M, Mir FA, et al. The accuracy of central SBP determined from the second systolic peak of the peripheral pressure waveform. J Hypertens. 2009;27:1784-1788.
13. Wilkinson IB, Mohammad NH, Tyrrell S, et al. Heart rate dependency of pulse pressure amplification and arterial stiffness. Am J Hypertens. 2002;15:24-30.
14. Takami T. Evaluation of arterial stiffness in morning hypertension under high-dose valsartan compared to valsartan plus low-dose diuretic. Hypertens Res. 2009;32:1086-1090.
15. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial. Circulation. 2001;104:1248-1254.
16. Safar ME, London GM. Therapeutic studies and arterial stiffness in hypertension: recommendations of the European Society of Hypertension. The Clinical Committee of Arterial Structure and Function. Working Group on Vascular Structure and Function of the European Society of Hypertension. J Hypertens. 2000;18:1527-1535.
17. Asmar RG, O'Rourke MF, Safar ME; on behalf of the REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004;43:92-99.
18. Stokes GS, Barin WS, Gilfillan KL. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. Hypertension. 2003;41:297-301.
19. Stewart AD, Millasseau SC, Kearney MT, Ritter JM, Chowienczyk PJ. Effects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans. Hypertension. 2003;42:915-918.
20. Safar ME. Mechanisms of systolic blood pressure reduction and drug therapy in hypertension. Hypertension. 2007;50:167-171.
21. Asmar RG, London GM, O'Rourke MF, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension. 2001;38: 922-926.
22. Agabiti-Rosei E, Mancia G, O'Rourke MF, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50:154-160.
23. Kuramoto K, Ichikawa S, Hirai A, Kanada S, Nakachi T, Ogihara T. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res. 2003; 26:201-208.
24. Nada T, Nomura M, Koshiba K, Kawano T, Mikawa J, Ito S. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung. 2007;57:698-670.
25. Fujisawa M, Yorikane R, Chiba S, Koike H. Chronotropic effects of azelnidipine, a slow-and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine. J Cardiovasc Pharmacol. 2009;53:325-332.
26. Yamamoto E, Lai ZF, Yamashita T, et al. Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. J Hypertens. 2006;24:2057-2069.
27. Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res. 2002;25:359-364.
28. Safar ME, Boudier HS. Vascular development, pulse pressure, and the mechanisms of hypertension. Hypertension. 2005;46:205-209.
29. Safar ME. Systolic hypertension in the elderly: arterial wall mechanical properties and the renin-angiotensin-aldosterone system. J Hypertens. 2005;23:673-681.
30. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens. 2005;18: 3S-10S.
31. Nichols WW, Estrada JC, Braith RW, Owens K, Conti CR. Enhanced external counterpulsation treatment improves arterial wall properties and wave reflection characteristics in patients with refractory angina. J Am Coll Cardiol. 2006;48:1208-1214.
32. Hashimoto J, Nichols WW, O'Rourke MF, Imai Y. Association between wasted pressure effort and left ventricular hypertrophy in hypertension: influence of arterial wave reflection. Am J Hypertens. 2008;21:329-333.
33. Iketani T, Iketani Y, Takazawa K, Yamashina A. The influence of the peripheral reflection wave on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res. 2000;23:451-458.
34. de Luca N, Asmar RG, London GM, O'Rourke MF, Safar ME. REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low-dose combination perindopril/indapamide in hypertensive subjects. J Hypertens. 2004;22:1623-1630.
35. Ito H, Ishii K, Iwakura K. Impact of azelnidipine treatment on left ventricular diastolic performance in patients with hypertension and mild diastolic dysfunction: multi-center study with echocardiography. Hypertens Res. 2009;32:895-900.
36. Hashimoto J, Imai Y, O'Rourke MF. Indices of pulse wave analysis are better predictors of left ventricular mass reduction than cuff pressure. Am J Hypertens. 2007;20:378-338.
37. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension. 2006;47:195-202.
38. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993;125:1148-1154.
39. Seccareccia F, Pannozzo F, Dima F, et al; Malattie Cardiovascolari Aterosclerotiche Istituto Superiore di Sanita Project. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health. 2001; 91:1258-1263.
40. Shokoji T, Fujisawa Y, Kiyomoto H, et al. Effects of a new calcium channel blocker, azelnidipine, on systemic hemodynamics and renal sympathetic nerve activity in spontaneously hypertensive rats. Hypertens Res. 2005;28:1017-1023.